Oncolytic herpes simplex virus vectors for cancer virotherapy

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 967-978

  Varghese, Susan ^a   Rabkin, Samuel D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer therapy; Clinical trials; HSV; Oncolytic virus

Indexed keywords

CYTOCHROME P450; CYTOSINE DEAMINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; ONCOLYTIC VIRUS; THYMIDINE KINASE; VIRUS VECTOR; PRODRUG;

ANIMAL MODEL; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; GENE EXPRESSION; GENE MUTATION; GLIOMA; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; MELANOMA; MULTIMODALITY CANCER THERAPY; NEUROPATHOLOGY; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SUICIDE GENE; TUMOR NECROSIS; VIRAL GENE DELIVERY SYSTEM; VIROTHERAPY; VIRUS REPLICATION; VIRUS VECTOR 716; VIRUS VECTOR G 207; VIRUS VECTOR NV 1020; ANIMAL; ANTIBODY SPECIFICITY; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETICS; METHODOLOGY; MUTATION; NEOPLASM; VIROLOGY;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ANIMALS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MUTATION; NEOPLASMS; ORGAN SPECIFICITY; PRODRUGS; SIMPLEXVIRUS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 0036901289     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700537     Document Type: Review

References (122)

1. Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-856.
2. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 2000;7:867-874.
3. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma [see comments]. Gene Ther. 2000;7:859-866.
4. Fong Y, Kemeny N, Jarnagin W, et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Am Soc Clin Oncol Ann Meeting. 2002:27.
5. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA. 1996;93:11307-11312.
6. Nishiyama Y. Herpesvirus genes: Molecular basis of viral replication and pathogenicity. Nagoya J Med Sci. 1996;59:107-119.
7. Rabkin SD, Hernaiz Driever P. Replication-competent herpes simplex virus vectors for cancer therapy. In: Rabkin SD, Hernaiz Driever P, eds. Replication-Competent Viruses for Cancer Therapy. Monographs in Virology. Basel: Karger; 2001;vol. 22:1-45.
8. Balfour HH Jr. Antiviral drugs. N Engl J Med. 1999;340:1255-1268.
9. Mellerick DM, Fraser NW. Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology. 1987;1.58:265-275.
10. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001;7:781-787.
11. Kaplitt MG, Tjuvajev JG, Leib DA, et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neuro-Oncol. 1994;19:137-147.
12. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology. 1988;166:41-51.
13. Pyles RB, Thompson RL. Evidence that the herpes simplex virus type 1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous system. J Virol. 1994;68:4963-4972.
14. Fang ZY, Tenser RB, Rapp F. Hepatic infection by thymidine kinase-positive and thymidine kinase-negative herpes simplex virus after partial hepatectomy. Infect Immun. 1983;42: 402-408.
15. Chen SH, Cook WJ, Grove KL, et al. Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant. J Virol. 1998;72:6710-6715.
16. Petrowsky H, Roberts GD, Kooby DA, et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol. 2001;75:7050-7058.
17. Yoon SS, Nakamura H, Carroll NM, et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 2000;14:301-311.
18. Fan H, Villegas C, Wright JA. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA. 1996;93:14036-14040.
19. Goldstein DJ, Weller SK. Herpes simplex virus type 1- induced ribonucleotide reductase activity is dispensible for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol. 1988;62:196-205.
20. Cameron JM, McDougall I, Marsden HS, et al. Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol. 1988;69:2607-2612.
21. Yamada Y, Kimura H, Morishima T, et al. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis. 1991;164:1091-1097.
22. Spector T, Averett DR, Nelson DJ, et al. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition. Proc Natl Acad Sci USA. 1985;82:4254-4257.
23. Coen DM, Goldstein DJ, Weller SK. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob Agents Chemother. 1989;33:1395-1399.
24. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.
25. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54:5745-5751.
26. Thompson RL, Wagner EK, Stevens JG. Physical location of a herpes simplex virus type-1 gene function(s) specifically associated with a 10 million-fold increase in HSV neurovirulence. Virology. 1983;131:180-192.
27. Chou J, Kern ER, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science. 1990;250:1262-1266.
28. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA. 1992;89:3266-3270.
29. Robertson LM, MacLean AR, Brown SM. Peripheral replication and latency reactivation kinetics of the nonneurovirulent herpes simplex virus type 1 variant 1716. J Gen Virol. 1992;73:967-970.
30. Whitley RJ, Kern ER, Chatterjee S, et al. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest. 1993;91:2837-2843.
31. MacLean AR, ul-Fareed M, Robertson L, et al. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the "a" sequence. J Gen Virol. 1991;72:631-639.
32. McKie EA, MacLean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex virus type 1 I (HSV-1) ICP34.5 null mutants in primary human CNS tumours - Evaluation of a potentially effective clinical therapy. Br J Cancer. 1996;74:745-752.
33. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 2001;98: 6396-6401.
34. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis. 1988;158:602-614.
35. Wong RJ, Kim SH, Joe JK, et al. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg. 2001;193:12-21.
36. Meignier B, Martin B, Whitley RJ, et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis. 1990;162:313-321.
37. Advani SJ, Chung SM, Yan SY, et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999;59:2055-2058.
38. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
39. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998;9:2177-2185.
40. Todo T, Ebright MI, Fong Y, et al. Oncolytic herpes simplex virus (G207) therapy: From basic to clinical. In: Maruta H, ed. Tumor-Suppressing Viruses, Genes, and Drugs. San Diego: Academic Press; 2002:45-75.
41. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and NV1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J. 2001;15:1306-1308.
42. Delman KA, Bennett JJ, Zager JS, et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther. 2000;11:2465-2472.
43. Toda M, Rabkin SD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. Hum Gene Ther. 1999;10:385-393.
44. Sundaresan P, Hunter WD, Martuza RL, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice. J Virol. 2000;74:3832-3841.
45. Varghese S, Newsome JT, Rabkin SD, et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther. 2001;12:999-1010.
46. Mashour GA, Moulding HD, Chahlavi A, et al. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol. 2001;169:64-71.
47. Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J Virol. 1999;73:6319-6326.
48. Yoon SS, Carroll NM, Chiocca EA, et al. Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy. J Gastrointest Surg. 1999;3:34-48.
49. Coukos G, Makrigiannakis A, Kang EH, et al. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res. 2000;6:3342-3353.
50. Chahlavi A, Todo T, Martuza RL, et al. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999;1:162-169.
51. Toyoizumi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther. 1999;10:3013-3029.
52. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 1998;5:160-165.
53. Bradley JD, Kataoka Y, Advani S, et al. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res. 1999;5:1517-1522.
54. Chung SM, Advani SJ, Bradley JD, et al. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 2002;9:75-80.
55. Blank SV, Rubin SC, Coukos G, et al. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther. 2002;13:627-639.
56. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639-645.
57. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885.
58. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 2001;8:89-98.
59. Jorgensen TJ, Katz S, Wittmack EK, et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia. 2001;3:451-456.
60. Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 2000;60:1193-1196.
61. Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest. 2000;105:1161-1167.
62. Kramm CM, Rainov NG, Sena-Esteves M, et al. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther. 1996;7:1989-1994.
63. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 1997;4: 222-228.
64. Yoon SS, Carroll NM, Chiocca EA, et al. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg. 1998;228:366-374.
65. Aghi M, Chou TC, Suling K, et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 1999;59:3861-3865.
66. Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 2000;7:939-946.
67. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16: 444-448.
68. Nakamura H, Mullen JT, Chandrasekhar S, et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 2001;61:5447-5452.
69. Pawlik TM, Nakamura H, Yoon SS, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res. 2000;60:2790-2795.
70. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 1999;10:2741-2755.
71. Carew JF, Kooby DA, Halterman MW, et al. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther. 2001;4:250-256.
72. Toda M, Martuza RL, Kojima H, et al. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998;160:4457-4464.
73. Todo T, Martuza RL, Dallman MJ, et al. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001;61:153-161.
74. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther. 2001;12:253-265.
75. Bennett JJ, Malhotra S, Wong RJ, et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg. 2001;233:819-826.
76. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA. 2000;97:2208-2213.
77. Mohr I, Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 1996;15:4759-4766.
78. Taneja S, MacGregor J, Markus S, et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA. 2001;98: 8804-8808.
79. Miyatake S, Iyer A, Martuza RL, et al. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997;71:5124-5132.
80. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma 34.5 gene-mediated virulence toward tumor and cycling cells. J Virol. 1999;73:7556-7564.
81. Nakamura H, Kasuya H, Mullen JT, et al. Regulation of herpes simplex virus gamma (1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest. 2002;109:871-882.
82. Miyatake SI, Tani S, Feigenbaum F, et al. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999;6:564-572.
83. Yamamura H, Hashio M, Noguchi M, et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 2001;61:3969-3977.
84. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol. 2000;18:723-727.
85. Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
86. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001;61:5453-5460.
87. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517-525.
88. Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001;61:6428-6436.
89. - herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Gene Ther. 2002;9:398-406.
90. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 2001;357:525-526.
91. Anderson WF. The current status of clinical gene therapy. Hum Gene Ther. 2002;13:1261-1262.
92. Walker JR, McGeagh KG, Sundaresan P, et al. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther. 1999;10:2237-2243.
93. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5:881-887.
94. Wong RJ, Joe JK, Kim SH, et al. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther. 2002;13:1213-1223.
95. Coukos G, Makrigiannakis A, Montas S, et al. Multiattenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther. 2000;7:275-283.
96. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. 1999;13:1325-1334.
97. Habib NA, Sarraf CE, Mitry RR, et al. EIB-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther. 2001;12:219-226.
98. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61: 7464-7472.
99. Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res. 1999;5:1523-1537.
100. Yeung S, Tufaro F, Qiang D, et al. Dextran sulfate enhances the systemic delivery of oncolytic herpes simplex virus for treatment of colorectal cancer. Mol Ther. 2001;3:S390.
101. Chahlavi A, Rabkin S, Todo T, et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999;6:1751-1758.
102. Miller CG, Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 2000;60:5714-5722.
103. Lambright ES, Kang EH, Force S, et al. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol Ther. 2000;2:387-393.
104. Todo T, Rabkin SD, Chahlavi A, et al. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther. 1999;10: 2869-2878.
105. Chen Y, Yu DC, Charlton D, et al. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum Gene Ther. 2000;11:1553-1567.
106. Burton EA, Bai Q, Goins WF, et al. Targeting gene expression using HSV vectors. Adv Drug Deliv Rev. 2001;53:155-170.
107. Wickham TJ. Targeting adenovirus. Gene Ther. 2000;7:110- 114.
108. Laquerre S, Anderson DB, Stolz DB, et al. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol. 1998;72:9683- 9697.
109. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol. 2001;3:745-750.
110. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332-1334.
111. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821-825.
112. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol. 2001;75:3474-3479.
113. Bergmann M, Romirer I, Sachet M, et al. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res. 2001;61:8188-8193.
114. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 2002;62:2306-2312.
115. Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res. 2000;6:4908-4914.
116. Coen DM, Kosz-Vnenchak M, Jacobson JG, et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA. 1989;86:4736-4740.
117. Markert JM, Malick A, Coen DM, et al. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery. 1993;32: 597-603.
118. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA. 1995;92:1411-1415.
119. Randazzo BP, Kesari S, Gesser RM, et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology. 1995;211: 94-101.
120. Pyles RB, Warnick RE, Chalk CL, et al. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther. 1997;8:533-544.
121. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998;5:121-130.
122. Robinson M, Liu B, Han Z, et al. ICP34.5 deleted herpes simplex virus 1 with enhanced oncolytic and anti-tumor properties: Preclinical studies. Mol Ther. 2002;5:S319.